These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29546691)

  • 1. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.
    Huang HY; Lin SJ; Zhao WG; Wu ZB
    Metab Brain Dis; 2018 Jun; 33(3):969-976. PubMed ID: 29546691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
    Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
    J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
    Arduc A; Gokay F; Isik S; Ozuguz U; Akbaba G; Tutuncu Y; Berker D; Kucukler FK; Aydin Y; Guler S
    J Endocrinol Invest; 2015 Apr; 38(4):447-53. PubMed ID: 25421155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A; Bhansali A; Masoodi SR
    Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
    Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
    Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
    De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
    Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
    Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
    Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactinoma: Clinical Characteristics, Management and Outcome.
    Irfan H; Shafiq W; Siddiqi AI; Ashfaq S; Attaullah S; Munir Alvi A; Khan SA; Abu Bakar M; Azmat U
    Cureus; 2022 Oct; 14(10):e29822. PubMed ID: 36337795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
    Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
    Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
    Yarman S; Kurtulmus N; Bilge A
    Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistant prolactinomas: a case series of 26 patients.
    Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
    Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
    Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
    Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
    Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
    J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
    Passos VQ; Souza JJ; Musolino NR; Bronstein MD
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3578-82. PubMed ID: 12161478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.